Knight to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference Pharmaceutical Investing
Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference Pharmaceutical Investing
AbbVie Announces Provincial Reimbursement for VRAYLAR® for the Treatment of Schizophrenia in Québec Pharmaceutical Investing
Abbott's FreeStyle Libre® Continuous Glucose Monitoring Systems Obtain Significantly Expanded Coverage for Medicare Beneficiaries Pharmaceutical Investing
BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR Pharmaceutical Investing
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma Pharmaceutical Investing
Moderna and Merck Announce mRNA-4157 , an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA , Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection versus KEYTRUDA Pharmaceutical Investing
Merck's KEYTRUDA® Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer Pharmaceutical Investing
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. Pharmaceutical Investing